U125 VALITUDE CRT-P,U128 VALITUDE X4 CRT-P,U225 VISIONIST CRT-P,U226 VISIONIST CRT-P,U228 VISIONIST X4 CRT-P
Guidant Corp. · Decision date Oct 22, 2025
What did the FDA decide?
FDA records P030005/S249 as a supplement to PMA P030005, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 22, 2025.
FDA approval order statement
to extend the time that solder paste can remain on the stencil before cleaning when building pulse generator printed circuit board assemblies
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 22, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P030005/S249
- Regulatory pathway
- PMA supplement
- Applicant
- Guidant Corp.
- Product code
- NKE
- Decision code
- OK30
- Decision date
- Oct 22, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Pulse generator, pacemaker, implantable, with cardiac resynchronization (CRT-P).
- Applicant
- Guidant Corp.
- Product code
- NKE
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P030005. Subsequent supplements may change the device or its indications.
FDA decision timeline
P030005 · Original PMA
CONTAK RENEWAL MODELS H125 AND H120 WITH THE MODEL 2865 VERSION 1.8 APPLICATION SOFTWARE
P030005/S248 · Related supplement
Accolade Cardiac Resynchronization Therapy Pacemakers, VALITUDE (Model U125); VALITUDE X4 (Model U128); VISIONIST (Model
P030005/S249 received
Application receipt date recorded by FDA.
P030005/S249 · FDA decision
30-Day Notice
P030005/S251 · Related supplement
VALITUDE (Model U125); VALITUDE X4 (Model U128); VISIONIST (Models U225, U226); VISIONIST X4 (Model U228)
P030005/S250 · Related supplement
VALITUDE (Model U125) VALITUDE X4 (Model U128) VISIONIST (Models U225, U226) VISIONIST X4 (Model U228) Firmware Vers
P030005/S247 · Related supplement
Accolade CRT Pacemakers (CRT-Ps): VALITUDE CRT-P U125; VALITUDE X4 CRT-P Model U128; VISIONIST CRT-P Models U225, U226
P030005/S252 · Related supplement
CONTAK RENEWAL MODELS H125 AND H120 WITH THE MODEL 2865 VERSION 1.8 APPLICATION SOFTWARE
P030005/S254 · Related supplement
VALITUDE, VALITUDE X4, VISIONIST, VISIONIST X4
P030005/S253 · Related supplement
INVIVE, INTUA, VISIONIST, VALITUDE
P030005/S255 · Related supplement
VALITUDE CRT-P IS1 EL (U125); VALITUDE CRT-P IS4 EL (U128); VISIONIST CRT-P IS1 EL (U225); VISIONIST CRT-P LV1 EL (U
P030005/S257 · Related supplement
VALITUDE (Model U125); VALITUDE X4 (Model U128); VISIONIST (Models U225, U226); VISIONIST X4 (Model U228)
Timeline entries are records held by MedtechLedger for P030005. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030005
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Guidant Corp. | PMA approval | Jan 26, 2004 | FDA | |
| Guidant Corp. | PMA supplement | Sep 22, 2025 | FDA | |
| Guidant Corp. | PMA supplement | Dec 17, 2025 | FDA | |
| Guidant Corp. | PMA supplement | Dec 19, 2025 | FDA | |
| Guidant Corp. | PMA supplement | Jan 8, 2026 | FDA | |
| Guidant Corp. | PMA supplement | Apr 1, 2026 | FDA | |
VALITUDE, VALITUDE X4, VISIONIST, VISIONIST X4P030005/S254 | Guidant Corp. | PMA supplement | Jun 3, 2026 | FDA |
INVIVE, INTUA, VISIONIST, VALITUDEP030005/S253 | Guidant Corp. | PMA supplement | Jul 1, 2026 | FDA |
| Guidant Corp. | PMA supplement | Jul 23, 2026 | FDA | |
| Guidant Corp. | PMA supplement | Oct 3, 2026 | FDA |
Explore the linked device profile
Other records with product code NKE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
BIOexpressP070008/S177 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 5, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Guidant Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4100 Hamline Ave. N, St Paul, MN, 55112
Sources and methodology
- Original FDA record: P030005/S249
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records







